Source: Annual Congress 2013 –Pulmonary circulation: basic science
Disease area: Interstitial lung diseases, Pulmonary vascular diseases



Rating:

Share or cite this content

Citations should be made in the following way:
N. Gambaryan, C. Meng, M. Humbert, I. Adcock, S. Wort (London, United Kingdom; Le Plessis-Robinson, France). H3K27 histone lysine methylation as potential therapeutic target in pulmonary arterial hypertension. Eur Respir J 2013; 42: Suppl. 57, 5157

Member's Comments

No comment yet.

Related content which might interest you: Implication of the histone methyltransferase EZH2 in pulmonary arterial hypertension Source: International Congress 2018 – Pathobiology of pulmonary hypertension Year: 2018 Epigenome-wide mapping of histone modification landscape in human pulmonary arterial hypertension Source: ERS Lung Science Conference 2016 Year: 2016 LSC Abstract – Epigenome-wide mapping of histone modification landscape in human pulmonary arterial hypertension Source: International Congress 2016 – New genomic targets in pulmonary disease Year: 2016 LSC Abstract – Histone deacetylase 7 mediated metabolic remodeling: A new crosslink between pulmonary hypertension and cancer Source: International Congress 2016 – The nature of pulmonary hypertension Year: 2016 microRNA-223 suppresses histone deacetylase 2 in chronic obstructive pulmonary disease Source: International Congress 2015 – Latest news on miRNAs in pulmonary research Year: 2015 Role and regulation of Jumonji C domain-containing histone demethylases 1A and 2B in pulmonary hypertension Source: International Congress 2016 – The nature of pulmonary hypertension Year: 2016 Role of class IIa histone deacetylases in the pathogenesis of pulmonary hypertension Source: International Congress 2014 – Pulmonary hypertension: pathobiology Year: 2014 Aberrant expression and activity of histone deacetylases in idiopathic pulmonary fibrosis (IPF) Source: Annual Congress 2013 –Translational studies in chronic lung diseases: from bedside to bench Year: 2013 Prevention of fetal programming of pulmonary vascular dysfunction by a histone deacetylase inhibitor Source: Annual Congress 2010 - Experimental pulmonary hypertension Year: 2010 Mutational and epigenetic analysis of the promoter region of BMPR2 gene in patients with pulmonary arterial hypertension Source: International Congress 2014 – Pulmonary hypertension: pathobiology Year: 2014 Epigenetic signature of right ventricular failure in pulmonary arterial hypertension Source: International Congress 2015 – Pulmonary hypertension: rare and hereditary causes of PAH Year: 2015 Global histone H3 lysine 4 (H3K4) dimethylation is an important prognostic factor in lung cancer Source: Annual Congress 2012 - New aspects of lung cancer biology Year: 2012 The pathophysiological role of novel pulmonary arterial hypertension gene SOX17 Source: Eur Respir J, 58 (3) 2004172; 10.1183/13993003.04172-2020 Year: 2021 Selective inhibition of BET bromodomain and their effect on nuclear factor-kappa B activation in pulmonary arterial hypertension Source: Annual Congress 2013 –Pulmonary circulation: basic science Year: 2013 Histone acetylation and deacetylation: importance in inflammatory lung diseases Source: Eur Respir J 2005; 25: 552-563 Year: 2005 RASSF1A regulates ROS-HIF axis in hypoxia driven pulmonary hypertension Source: International Congress 2016 – Pulmonary hypertension: novel insights Year: 2016 Iron deficiency in pulmonary arterial hypertension: a potential therapeutic target Source: Eur Respir J 2011; 38: 1453-1460 Year: 2011 LATE-BREAKING ABSTRACT: The bromodomain-containing protein 4: the epigenetic origin of the oncogenic signature in pulmonary hypertension Source: International Congress 2014 – New technologies and biomarkers in lung disease Year: 2014 Survivin inhibition as a potential target for pulmonary arterial hypertension Source: International Congress 2019 – Pulmonary hypertension: novelties from the bench Year: 2019